The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sanofi and Regeneron’s Dupixent (dupilumab) ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...
Tarrytown, New York Wednesday, March 4, 2026, 13:00 Hrs [IST] ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).
Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.
Regeneron Pharmaceuticals and Sanofi said a key European regulatory committee has recommended expanded approval of their blockbuster anti-inflammatory drug Dupixent for younger patients with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results